周三盘中,曼恩凯德生物医疗(MNKD)股价大跌12.16%,主要原因是公司公布的季度业绩未能达到分析师预期。
根据公司最新发布的财报,截至6月30日的季度,曼恩凯德生物医疗实现收入7653万美元,同比增长5.7%,但低于分析师预期的7860万美元。每股收益方面,公司报告盈亏平衡,未能达到分析师平均预期的0.05美元每股。值得注意的是,公司本季度净收入为66.8万美元。
这一业绩表现明显低于市场预期,导致投资者信心受挫。事实上,曼恩凯德生物医疗股价今年以来已下跌37.9%,显示出公司面临的持续压力。尽管如此,分析师对该公司的平均评级仍维持在"买入",12个月目标价中位数为9.00美元,较上一交易日收盘价高出约55.7%。这表明分析师仍对公司的长期前景保持乐观,但短期内业绩不及预期可能会继续给股价带来压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.